Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

telaprevir

telaprevir
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Incivek TABLET, ORAL 375 mg      
Comments:

Incivek medication guide

INCIVEK is a new oral protease inhibitor for the treatment of hepatitis C in combination with peginterferon and ribavirin. It must be administered every 8 hours with a high-fat meal (i.e., at least 2 oz potato chips, 1 cup ice cream, 3 tbsp peanut butter, etc). It also has many drug interactions via the CYP-3A4 system and adverse reactions, including severe rashes and hematological reactions. INCIVEK is an automatic pharmacy consult to assure proper dosing and diet schedule, drug interaction screening and adverse reaction monitoring.

INCIVEK is classified as formulary status for patients continuing therapy from home. Patient may use home supply if available. Defer initiation of the drug to the outpatient setting where a financial management plan can be developed for the patient.

Reviewed: September 27, 2011

Pulled from the market October 2014.

Last updated: Feb. 7, 2017






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved